Tun AM, Maliske S, Wang Y, et al. - Researchers studied the role of progression-free survival (PFS) at 24 months (PFS24) as a landmark following autologous stem cell transplant (ASCT) in patients suffering from relapsed or refractory (RR) diffuse large B-cell lymphoma (DLBCL). This study included 437 patients with RR DLBCL after frontline R-CHOP or R-CHOP-like immunochemotherapy (IC) who had salvage therapy and ASCT. Following a median post-ASCT follow-up of 8.0 years, a relapse (or disease progression) occurred in 215 patients, in 180 within 2 years and in 35 after 2 years. The estimated median PFS and overall survival post-attaining PFS24 was 10.0 and 11.5 years, respectively. Post-achieving PFS24, there were similar lymphoma related and unrelated death rates. For all patients who suffered a post-ASCT relapse, the median post-relapse survival (PRS) was estimated to be 0.7 years, and better PRS was observed in relation to late relapse. Findings revealed post-ASCT PFS24 as a crucial prognostic predictor of post-ASCT results in RR DLBCL cases post-frontline IC.